Clinical Trial Search

Primary: 2 Year Disease-free Survival . — 9 percentage of participants

Primary: The Percentage of Patients Who Had a Curative (R0) Liver Metastasectomy Following Protocol Treatment, i.e., Metastatic Disease That Can be Completely Resected and/or…

Primary: Evaluation of Toxicity Related to Electrochemotherapy (Toxicity, Symptoms) — 0; 0; 0 events

Primary: Progression-free Survival Rate at 9 Months — 30; 26 Participants

Primary: Progression-Free Survival (PFS) at Any Site — 10.7; 10.2 Months — p=0.551

Primary: Overall Survival (OS) — 25.9; 25.0 months — p=0.43

Primary: Overall Response Rate (ORR) — 75 percentage of evaluable participants

Primary: Number of Participants With at Least One Dose Limiting Toxicity — 0; 0; 1 participants with DLTs

Primary: Success of DEBIRI-M1 Procedure as a Measure of Feasibility (Percentage of Successful Treatments) — 100 percentage of successful treatments

Primary: Percentage of Participants Achieving Complete Resection (R0 Resection) — 30.0 percentage of participants

Primary: Tumor Response — 31; 16 participants

Primary: Change in Tumor-infiltrating Lymphocytes (TILs) in the Colorectal Cancer Lesions — 7.25 fold change — p=0.046

Primary: Evaluation of Safety Related to Electrochemotherapy — 20; 3; 0; 0 Participants

Primary: Disease Response Rate — 12.5 percentage of participants with response

Primary: Complete Hepatic Response Rate at 3 Months — 79 percentage of participants

Primary: Percentage of Participants With Complete Resection or Residual (Microscopic or Macroscopic) Tumor — 48.7; 61.0; 33.3; 51.2 percentage of participants — p=0.2707

Primary: Objective Response Rate (ORR) in the Intent-to-treat (ITT) Analysis Set — 54.5 percentage of participants

Primary: Number of Patients With Adverse Events — 5; 0 Participants

Primary: Response Rate — 2; 13; 21; 1 Participants

Primary: Recurrence-free Survival at 2 Years — 13; 10 participants

Primary: Progression Free Survival — 8.0; 7.2 Months — p=0.0013

Primary: Quality of Surgery for Primary Tumor — 2; 1; 15; 19 Participants — p=0.719

Primary: Incidence of Adverse Events and Dose Limiting Adverse Events — 0; 69; 47; 44 percentage of participants

Primary: Overall Survival — 333; 290 days — p=0.4593

Primary: Count of Participants With Serious and Non-serious Adverse Events Assessed by the Common Terminology Criteria in Adverse Events (CTCAE v4.0) — 6; 9 Participants

Primary: Number of Subjects Who Experience Grade 3-5 Toxicity as a Measure of Safety and Tolerability. — 20 Participants

Primary: Disease Free Survival (DFS) — 21.6; 24.7 months — p=0.468

Primary: Participants With Recurrence Free Survival for Colorectal Cancer Participants With Resected Liver Metastases — 69; 47 percentage of participants

Primary: Progression-free Survival Rate — 53.2 percentage of participants

Primary: Percentage of Participants With Conversion From Unresectable to Resectable Liver Metastases — 42.2 percentage of participants